Abstract
The patient is a 65-year-old man, who underwent curative resection for maxillary sinus carcinoma after chemoradiation. Lung metastases were observed two months following resection, and were treated with S-1 at a dose of 120 mg/day. One course of the S-1 administration regimen consisted of 2 weeks and a 1-week interval. The patient achieved long survival for 527 days with no adverse reaction. Therefore, this treatment on an outpatient basis greatly contributed to his quality of life. We consider S-1 as a first-line anti-cancer drug for tumor dormancy therapy.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Aged
-
Antimetabolites, Antineoplastic / therapeutic use*
-
Carcinoma, Squamous Cell / drug therapy*
-
Carcinoma, Squamous Cell / secondary
-
Carcinoma, Squamous Cell / surgery
-
Combined Modality Therapy
-
Drug Administration Schedule
-
Drug Combinations
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / secondary*
-
Male
-
Maxillary Sinus Neoplasms / drug therapy*
-
Maxillary Sinus Neoplasms / pathology
-
Maxillary Sinus Neoplasms / surgery
-
Oxonic Acid / therapeutic use*
-
Survivors
-
Tegafur / therapeutic use*
Substances
-
Antimetabolites, Antineoplastic
-
Drug Combinations
-
S 1 (combination)
-
Tegafur
-
Oxonic Acid